Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.42 |
| ▸ | HTR2A | P28223 | 1/20 | 0.41 |
| ▸ | CASP3 | P42574 | 2/20 | 0.41 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.39 |
| ▸ | MDM4 | O15151 | 1/20 | 0.39 |
| ▸ | TP53 | P04637 | 1/20 | 0.39 |
| ▸ | MGLL | Q99685 | 1/20 | 0.37 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31520512 | 0.95 | CYP1A2 (0.43) | KMT2AHTR2ACASP3EPHX2MAPT | |
| SCHEMBL31520535 | 0.93 | HTR2A (0.42) | KMT2AHTR2ACASP3MGLL | |
| SCHEMBL31520542 | 0.93 | KMT2A (0.40) | KMT2AHTR2ACASP3RAB9AMDM4 | |
| SCHEMBL31520537 | 0.91 | KMT2A (0.41) | KMT2AHTR2ACASP3MDM2 | |
| SCHEMBL31520531 | 0.90 | HTR2A (0.41) | KMT2AHTR2ACASP3MAPTRAB9A | |
| SCHEMBL31520525 | 0.90 | TLR2 (0.37) | KMT2AHTR2ACASP3EPHX2 | |
| SCHEMBL31520517 | 0.90 | HTR2A (0.39) | KMT2AHTR2ACASP3MAPTHTT | |
| SCHEMBL31520523 | 0.90 | HTR2A (0.39) | KMT2AHTR2ACASP3EPHX2MDM2 | |
| SCHEMBL31520507 | 0.89 | MAPT (0.37) | KMT2AHTR2ACASP3EPHX2MAPT | |
| SCHEMBL31520518 | 0.89 | HTR2A (0.43) | KMT2AHTR2ACASP3EPHX2MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4537854-A1 | COMPOUND FOR CONJUGATION, CONJUGATE AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | Formosa Laboratories, Inc. (TW) | 2025-04-16 | — | — | EP | disclosed |
| US-20250114473-A1 | COMPOUND FOR CONJUGATION, CONJUGATE AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | FORMOSA LABORATORIES, INC. (TW) | 2025-04-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250114473-A1 | COMPOUND FOR CONJUGATION, CONJUGATE AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | ABCB1, UGT1A9, ABCG2 | KMT2A 1259/4885HTR2A 2775/4885CASP3 2905/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.